-
Signature
-
/s/ Jeffrey Farrow, Attorney-in-Fact
-
Issuer symbol
-
TARS
-
Transactions as of
-
04 Mar 2026
-
Net transactions value
-
-$641,421
-
Form type
-
4
-
Filing time
-
05 Mar 2026, 16:03:37 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Neervannan Seshadri |
Chief Operating Officer |
C/O TARSUS PHARMACEUTICALS, INC., 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE |
/s/ Jeffrey Farrow, Attorney-in-Fact |
05 Mar 2026 |
0001827584 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
TARS |
Common Stock |
Sale |
$641,421 |
-8,366 |
-11% |
$76.67 |
70,817 |
04 Mar 2026 |
Direct |
F1 |
| holding |
TARS |
Common Stock |
|
|
|
|
|
475 |
04 Mar 2026 |
By daughter |
F2 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: